Since inhibitors of human epidermal growth factor receptor 2 (HER2), such as trastuzumab, pertuzumab, and lapatinib, were introduced for the treatment of HER2-overexpressing GC, the outcome of advanced gastric cancer patients has been significantly improved (Bang et al., 2010). Here, ERBB2 is linked to gastric cancer.